GSK in talks to buy Human Genome Sciences

  • GlaxoSmithKline held talks this weekend with Human Genome Sciences to dicuss a deal to acquire it for some $2.6 billion, according to sources familiar with the matter.

    The British pharmaceutical giant has been pursuing the U.S. biotech company for three months.

    It may reportedly up its previous $13 per share offer for Human Genome and a deal may be signed during the course of the day, one of the sources said.

    Human Genome rejected GlaxoSmithKline's $2.6 billion offer in April as it was too low and launched an auction process.

    The U.S. company set itself a July 16 deadline for finding a higher bid but interest has been limited as GSK, its long-time partner, owns the marketing rights to its drugs.